NORGINE EXPANDS ITS PARTNERSHIP WITH APHARM TO COMMERCIALISE ZIVEREL® PLUS

Back to media releases
Next media release
09 November 2017

CORPORATE MEDIA RELEASE

NORGINE EXPANDS ITS PARTNERSHIP WITH APHARM TO COMMERCIALISE ZIVEREL® PLUS

 

Amsterdam. The Netherlands. Thursday 9 November 2017. 13:00 CET. Norgine B.V. today announced that it has expanded its partnership with Apharm s.r.l. by entering into an exclusive distribution deal for ZIVEREL® PLUS, a line extension of ZIVEREL®. This deal expands on Norgine’s existing collaboration with Apharm s.r.l. under which Norgine is distributing ZIVEREL® in Europe, Australia and New Zealand.

ZIVEREL® PLUS is a Class III medical device for the protective treatment of the oesophageal mucosa. ZIVEREL® PLUS additionally contains the antacid magaldrate and has been formulated to further enhance the protection and repair of the oesophagus, and to give even more rapid relief from the symptoms of gastroesophageal reflux than is already seen with ZIVEREL®[1]. It is expected that ZIVEREL® PLUS will be launched in 2019.

Peter Martin, COO at Norgine said: “The addition of ZIVEREL® PLUS to our gastroenterology portfolio continues to demonstrate Norgine’s strong expertise in commercialising transformative treatment options for patients who suffer from digestive diseases such as gastroesophageal reflux disease (GERD).” He added: “This new partnership continues to leverage the strong working relationship that Norgine has developed with Apharm and we are looking forward to launching the product in 2019.”

Paolo Pizzoni, Managing Director of Apharm said: “We are pleased to expand our partnership with Norgine. This new development, building on the current ZIVEREL® formulation already successfully launched, is aimed to offer additional treatment options to patients with GERD.”

Gastroesophageal reflux disease is prevalent worldwide, and disease burden may be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.[2]

ZIVEREL®[3] is a non-reimbursed medical device, that does not require a medical prescription. Prices are applicable per country.

Notes to Editors:

About Norgine

 

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

 

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

 

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

ZIVEREL, NORGINE and the sail logo are registered trademarks of the Norgine group of companies.

 

About Apharm

Apharm is a dynamic Italian based pharmaceutical company whose core business is the research and development of new products and registration of innovative patents that are licensed on a global basis.

Apharm operates in a number of therapeutic area but is most active in the fields of gastroenterology, orthopaedic and dermatology/aesthetics.

Constantly committed to improve people’s life quality in terms of health and wellbeing, Apharm carries out an active role in discovering and treating pathologies of high social impact.

For more information, please visit www.apharm.it or contact Mr. Paolo Pizzoni, Managing Director and co-founder of Apharm (paolo.pizzoni@apharm.it).

 

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Follow us @norgine

 

 


GL/ZIV/1017/0014

 

[1] Savarino V et al. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease–efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631-42.

[2]  Dent J et al. Epidemiology of gastro-oesophageal reflux disease: A systematic review.  Gut 2005;54:710-717

[3] ZIVEREL® Instructions for Use, 2017.